Department of Pediatrics, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Department of Child Neurology, Okayama University Hospital, Okayama, Japan.
Ann Hematol. 2024 Nov;103(11):4805-4809. doi: 10.1007/s00277-024-06000-7. Epub 2024 Sep 17.
Pediatric ALK-positive anaplastic large cell lymphoma is a rare subtype of non-Hodgkin lymphoma, and approximately 30% of patients relapse following treatment with conventional chemotherapy. Alectinib monotherapy has demonstrated excellent activity in relapsed and refractory ALCL, but its role as a maintenance therapy after hematopoietic cell transplantation is unclear. We experienced a relapse case of pediatric ALK-positive ALCL with central nervous system involvement treated with alectinib maintenance therapy following cord blood transplantation. The patient has maintained complete remission for more than 3 years after transplantation. There were no remarkable adverse effects that led to discontinuation of alectinib.
儿童间变性大细胞淋巴瘤（ALK 阳性）是一种罕见的非霍奇金淋巴瘤亚型，约 30%的患者在接受常规化疗后复发。艾乐替尼单药治疗在复发和难治性间变性大细胞淋巴瘤中显示出极好的活性，但它在造血干细胞移植后的维持治疗中的作用尚不清楚。我们经历了一例儿童间变性大细胞淋巴瘤（ALK 阳性）伴中枢神经系统侵犯的病例，在脐带血移植后接受艾乐替尼维持治疗。该患者在移植后 3 年以上仍保持完全缓解，无导致艾乐替尼停药的显著不良反应。
